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Quadrupole-Orbitrapa b s t r a c t
Exposure of DNA to endo- and exogenous DNA binding chemicals can result in the formation of DNA
adducts and is believed to be the first step in chemically induced carcinogenesis. DNA adductomics is a
relatively new field of research which studies the formation of known and unknown DNA adducts in DNA
due to exposure to genotoxic chemicals. In this study, a new UHPLC-HRMS(/MS)-based DNA adduct
detection method was developed and validated. Four targeted DNA adducts, which all have been linked
to dietary genotoxicity, were included in the described method; O6-methylguanine (O6-MeG), O6-car-
boxymethylguanine (O6-CMG), pyrimidopurinone (M1G) and methylhydroxypropanoguanine (CroG). As
a supplementary tool for DNA adductomics, a DNA adduct database, which currently contains 123
different diet-related DNA adducts, was constructed. By means of the newly developed method and
database, all 4 targeted DNA adducts and 32 untargeted DNA adducts could be detected in different DNA
samples. The obtained results clearly demonstrate the merit of the described method for both targeted
and untargeted DNA adduct detection in vitro and in vivo, whilst the diet-related DNA adduct database
can distinctly facilitate data interpretation.
© 2015 Elsevier B.V. All rights reserved.haecke).
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When a genotoxic chemical binds to DNA, chemically stable
DNA adducts can be introduced to the DNA sequence. Carcino-
genesis is known to arise due to a combination of both genetic and
environmental factors, and DNA adduct formation is considered to
be the first step in chemically induced carcinogenesis [1,2].
Different ‘endogenous’ DNA adduct types are formed continuously
due to normal physiological processes like oxidative stress and
inflammation. The same and also other DNA adduct types can be
formed due to exposure to environmental chemicals, which results
in the occurrence of ‘exogenous’ DNA adduct levels [3].
It has been demonstrated that exogenous DNA adduct formation
causally links the consumption of aflatoxin B1 contaminated food
to hepatocellular carcinoma incidence [4] and more recently, re-
searchers also established a causal link between the smoking of
tobacco, the formation of PAH-DNA adducts (PAH ¼ polycyclic ar-
omatic hydrocarbons) and cervical cancer [5]. In consequence,
research on DNA adduct related carcinogenesis due to certain
environmental factors has gained an intelligible interest during the
past decade.
Colon cancer incidence is mainly influenced by the presence (or
absence) of particular environmental factors, as literature states
that up to 70% of colon cancer cases could be prevented by dietary
changes [6,7]. For example, in developed (‘Western’) countries, high
red and processed meat consumption has been linked to a signifi-
cantly higher colon cancer incidence in both men and women.
Different hypotheses have been put forward to substantiate this
meatecancer relationship. The two remaining hypotheses howev-
er, discuss the role of N-nitroso compound (NOC) and aldehyde
formation in the human gut upon digestion of red and processed
meat [8]. Both NOCs and aldehydes can bind to DNA nucleobases,
resulting in the possible formation of a multitude of DNA adducts
[6,9].
To study the role of meat consumption in particular, and the
human diet and exosphere in general, in the initiation and pro-
gression of cancer, the development of a highly specific and sen-
sitive method for the detection of diet-related DNA adducts could
prove very useful.
Different analytical methods such as immunoassays, immuno-
histochemistry, 32P-postlabeling, GC- or HPLC-ECD, HPLC-FD, GC-
or (HP)LC-MS, (LC-)NMR, LM-PCR and AMS [10,11] have been
developed for the detection of specific or bulky DNA adducts.
Although every analytical method has its advantages, MS may
prove to be the most useful analytical method for the screening,
detection and quantification of diet-related DNA adducts [11,12].
The most widely used DNA adduct detection technique is 32P-
postlabeling, which has excellent sensitivity, but lacks adequate
specificity [13]. Ultra-High Performance Liquid Chromatography
(UHPLC) combined with High Resolution MS (HRMS) detection
techniques on the other hand, enable accurate identification of
analytes based on chemical composition and exact compound
mass. Furthermore, MS techniques can also provide structural in-
formation and due to ongoing technical improvements, MS
currently offers an excellent qualitative and quantitative tool for
DNA adduct research [10,14e16]. Although the advantages of HRMS
are clear, it may lack sufficient sensitivity for quantification of low
levels of DNA adducts. An alternative approach is the use of MS/MS,
which most often brings about lower detection limits, enabling a
more accurate quantitation. A recent advance in MS technology
now combines the specificity of HRMS and the sensitivity of triple
quadrupole MS/MS by combining both methodologies in ‘hybrid
quadrupole MS’ systems [17,18]. In other words, MS can easily
measure low DNA adduct levels with the highest specificity,
enabling simultaneous identification and quantification of differentcompounds.
In light of these advances, the possibilities of a hybrid HRMS/MS
approach was investigated through the development and valida-
tion of a method capable of quantifying 4 DNA adducts that may be
related to the meat and colon cancer hypothesis: O6-methyl-
guanine (O6-MeG), O6-carboxymethylguanine (O6-CMG), pyrimido
[1,2-a]purin-10(1H)-one (M1G) and a-methyl-g-hydroxy-1,N2-
propanoguanine (CroG). The formation of O6-MeG and O6-CMG has
been linked to NOC formation in the gut during meat digestion [6],
while M1G and CroG can be produced when diet-related or
endogenously formed malondialdehyde or crotonaldehyde (both
lipid peroxidation products) bind to guanine (G) in DNA [9]. Besides
the described targeted approach (UHPLC-HRMS/MS), an untargeted
full scan UHPLC-HRMS approach was explored to enable future
DNA adductomics research. In addition, to facilitate DNA adduct
research, known diet-related DNA adducts were defined and listed
in an in-house database.
2. Materials and methods
2.1. Reagents and chemicals
Standards of M1G, CrodG (a-methyl-g-hydroxy-1,N2-propano-20-
deoxyguanosine) and their internal standards M1G-13C3 and
CrodG-13C,15N2 were obtained from Toronto Research Chemicals
(Toronto, Canada). O6-CMdG (O6-carboxymethyl-20-deoxyguanosine)
was kindly provided by Prof. S. Moore (Liverpool John Moores
University, UK), whilst O6-MedG (O6-methyl-20-deoxyguanosine),
O6-d3-MedG and a guanine (G) standard were purchased at Sigma-
Aldrich (St. Louis, USA).
Ethyldiazoacetate (EtDA) (the precursor of potassiumdiazoacetate
(KDA)), crotonaldehyde (CRO) and 1,1,3,3-tetramethoxypropane (the
precursor of malondialdehyde (MDA) were obtained from Sigma-
Aldrich (St. Louis, USA) as well.
2.2. Preparation of stock and working solutions
Prior to preparation of stock and working solutions, O6-CMdG,
O6-MedG, O6-d3-MedG, CrodG and CrodG-13C,15N2 were hydro-
lyzed from guanosines (nucleotides) to guanines (nucleobases) in
0.1 M formic acid at 80 C during 30 min [19]. All standards were
diluted in MeOH and stored (20 C) in stock and working solu-
tions of respectively 500 ng mL1 and 5 ng mL1.
An 800 mM stock solution of KDA was synthesized through
alkaline hydrolysis of EtDA [20]. After further dilution with phos-
phate buffered saline (PBS), a working solution of 20 mM KDA was
obtained (Caution!: KDA is highly toxic and carcinogenic).
CRO was diluted to a stock and working solution of 800 and
20mM in PBS (Caution! CRO is highly toxic and carcinogenic). Stock
and working solutions of both KDA and CRO were stored in dark
glass bottles at 80 C.
The precursor of MDA; 1,1,3,3-tetramethoxypropanewas diluted
in acidified (HCl, pH 2), deionized water and kept at 45 C during
1 h to ensure full release of MDA. Working solutions of MDA
(20 mM) were freshly prepared prior to each experiment.
2.3. DNA hydrolysis and DNA adduct purification
DNA adducts were extracted and purified according to the
protocol of Vanden Bussche et al. [19], during which DNA samples
are initially subjected to DNA hydrolysis (30 min, 80 C) in 0.1 M
formic acid to cleave both adducted and non-adducted DNA
nucleobases from the DNA sequence. This is then followed by pu-
rification and sample cleanup by means of solid-phase extraction
(SPE) (Oasis® HLB cartridges (1 cc, 30 mg) Waters (Milford, USA)).
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vacuum (90min, 20 C) and resuspended in 100 mL of mobile phase.
The obtained DNA adduct samples were stored at 20 C until LC-
MS analysis.2.4. UHPLC-HRMS(/MS) analysis
Chromatographic separation of DNA adducts was carried out by
reversed phase chromatography. To ensure an optimal chromato-
graphic separation and resolution, several column types were
tested, including Nucleodur ISIS (5 mm 3  150 mm and
4  250 mm) and Pyramid (1.8 mm 2  100 mm) (Machery-Nagel,
Düren, Germany), Hypersil Gold (1.9 mm 2.1  100 mm, Thermo
Fisher Scientific, San Jose, USA), Luna NH2 (5 mm 4.60  150 mm,
Phenomenex, Torrance, USA), Acquity BEH C18 (1.7 mm
2.1  100 mm), HSS C18 (1.8 mm 2.1  100 mm) and HSS T3 (1.8 mm
2.1  100 mm, Waters, Milford, MA, USA). Different mobile phases
containing different percentages of solvent modifiers including
acetic or formic acid and ammonium bicarbonate, and solvents i.e.
water, methanol and acetonitrile were tested in parallel, and were
pumped at 300 mL per min by an Accela 1250 pump coupled to an
Accela Autosampler (Thermo Scientific, San Jose, USA).
MS analysis was performed on a hybrid Quadrupole-Orbitrap
High Resolution Accurate Mass Spectrometer (HRAM, Q-Exac-
tive™, Thermo Fisher Scientific, San Jose, USA) coupled to a heated
elektrospray ionization (HESI-II) source. All HESI and HRMS(/MS)
parameters were optimized for the 4 targeted compounds and their
internal standards. Chemical composition of the studied DNA ad-
ducts, theoretical and measured masses, observed mass deviation,
monitoredMS/MS ions and expected retention time (RT) are shown
in Table 1.
General instrument control and data processing were per-
formed with Xcalibur™ 3.0 and ToxID™ software (Thermo Fisher
Scientific, San Jose, USA).2.5. Validation in Calf Thymus DNA
Currently, guidelines or regulations for the validation of
analytical methods for the detection of DNA adducts in biological
matrices are not available. The US Food and Drug Administration
(FDA) did announce its intent to publish guidelines for biomarker
detectionmethods, but a final draft has not yet been published [21].
Therefore, the guidelines for chemical methods described by the US
FDA [22] and the EU Commission Directive 2002/657/EC [23] on the
performance of analytical methods were taken into account. The
described analytical method was validated by assessment of spec-
ificity, selectivity, linearity, precision and trueness with full scan
HRMS. Quantification and detection limits were assessed with and
for the full scan HRMS, SIM-HRMS and SIM-HRMS/MS method. The
matrix in which all validation parameters were tested, consisted of
the commercially available Calf Thymus DNA (CT-DNA). LyophilizedTable 1
Chemical composition, theoretical mass, measured mass, observed mass deviation, monit
of the studied DNA adducts.




O6-CMG C7H7N5O3 210.06217 210.06194
O6-MeG C6H7N5O 166.07234 166.07225
d3-MeG C6H4[2H]3N5O 169.09117 169.09100
M1G C8H5N5O 188.05669 188.05649
13C3-M1G C5[13C]3H5N5O 191.06675 191.06655
CroG C9H11N5O2 222.09855 222.09843
13C15N2-CroG C8[13C][15N]2H11N3O2 225.09598 225.09560CT-DNA was purchased from Rockland (Gilbertsville, Pennsylvania,
USA) and stored at 4 C in Tris-EDTA buffer (1 mg mL1).
2.6. DNA adducts in CT-DNA treated with genotoxic compounds
The genotoxic compounds KDA, MDA and CRO were supple-
mented to CT-DNA in triplicate and incubated overnight (37 C) to
allow interaction and subsequent DNA adduct formation. KDA was
added to 100 mg of DNA in 3 different concentrations (1 mM,
2.5 mM and 5 mM). Separately, both MDA and CRO were added to
100 mg of DNA as well, but in concentrations of 0.1 mM, 0.25 mM
and 0.5 mM. After overnight incubation, DNA adducts were
extracted and analyzed. An equal amount of CT-DNA (100 mg), not
treated with genotoxic compounds, was used as a negative control
and to correct for intrinsically present DNA adduct levels.
2.7. DNA adduct profiling in colon biopsies
Left colon tumors were obtained during colonoscopy of 10 in-
dividuals diagnosed with colon cancer at the Ghent University
Hospital. The average age of the patients was 74, the youngest being
58 and the eldest 83. The group consisted of 7 men and 3 women.
All resected samples were poorly to moderately differentiated
primary adenocarcinomas which were submerged and stored in
95% of ethanol at 80 C. Two samples were retrieved in 2006 and
2007, but most were gathered in 2012 and 2013.
A Qiagen blood & tissue kit (Qiagen, Hilden, Germany) was used
for the extraction of DNA from the tissue samples according to the
protocol provided by the manufacturer. The concentration and
purity of the extracted DNA was determined with a Nanodrop ND-
1000 spectrophotometer (Isogen Lifescience, Ijsselstein, The
Netherlands). Following this, the obtained DNA in each sample was
hydrolyzed and DNA adducts were purified according to the pro-
tocol described under ‘2.3 DNA hydrolysis and DNA adduct
purification’.
3. Results
3.1. UHPLC-HRMS(/MS) settings optimization
The Acquity BEH C18 Waters column and the use of 0.05% of
acetic acid in water and 100% MeOH as mobile phases provided
optimal results for baseline peak separation, signal to noise ratio,
peak area, peak shape and RT of all eluting targeted DNA adducts.
The amount of MeOH was increased linearly from 0.85 min,
reaching 50% after 4 min, which was then immediately followed by
1 min of 100% MeOH. For the remaining 2 min, the column was re-
equilibrated at 95:5 0.05% acetic acid in water:MeOH.
Three different MS acquisition modes were assessed: full scan
MS, SIM-MS (selected ion monitoring) and SIM-MS/MS. Both









1.09 152.05663 40 1.5
0.54 134.04613 60 2.8
1.01 134.04617 60 2.7
1.06 97.04008 60 3.0
1.05 100.05006 60 3.0
0.54 152.05670 40 3.5
1.69 155.05392 40 3.5
Fig. 1. Chromatogram of O6-MeG (a), d3-MeG (b), O6-CMG (c), M1G (d), 13C3-M1G (e),
CroG (f) and 13C15N2-CroG (g) in CT-DNA with SIM-MS/MS acquisition.
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DNA adducts, but also the future analysis of all untargeted DNA
adducts of interest, thus facilitating the use of this method as an
“omics” tool. Likewise, the full MS scan range was held at
70e700 m/z to enable an untargeted analysis next to the targeted
analysis. A scan range of 100e250 m/z was chosen for the targeted
analysis in SIM-MS and SIM-MS/MS. Ultimately, the chosen scan
resolution for full MS was ‘ultra high’ (100,000 FWHM (Full Width
Half Maximum)), using 3 microscans. Optimal maximum inject
time was 500 ms and the automatic gain control target was best
operated in ‘high dynamic range’ (3 e6). Sheath gas, auxiliary gas
and sweep gas flow rate were set at 35, 5 and 2 arbitrary units.
Optimal spray voltage, capillary temperature, capillary voltage and
heater temperature were kept at 4 kV, 280 C, 40 V (positive or
negative, dependent on polarity switch) and 330 C respectively. S-
lens RF-level was set at 90 and the same settings were applied for
all acquisition types. However, a resolution of 70,000 and 17,500
FWHM appeared sufficient for respectively SIM-MS and SIM-MS/
MS, whilst a maximum inject time of 250 ms was applied.
Normalized collision energy (NCE) and monitored product ions in
MS/MS for each targeted DNA adduct and their internal standards
are shown in Table 1. A chromatogram and full scan mass spectrum
of all targeted compounds and their internal standards are pre-
sented in Figs. 1 and 2.
3.2. Validation of the full HRMS method for the targeted detection
of DNA adducts
3.2.1. Specificity
The specificity of the HRMS method for the detection of O6-
CMG, O6-MeG and CroG was assessed by analyzing over 21 blank
CT-DNA samples and over 108 spiked CT-DNA samples. Spiked
samples were fortified with a mixture of all DNA adducts, or each
DNA adduct separately at three different concentrations levels
(2.50, 5.00 and 7.50 ng mL1 for O6-CMG and O6-MeG; 0.25, 0.50
and 0.75 ng mL1 for CroG). Comparison of the obtained chro-
matograms of blank and spiked DNA samples demonstrated that
the DNA matrix did not cause interference for O6-CMG, O6-MeG
and CroG detection. In addition, spiking of O6-CMG, O6-MeG and
CroG lead to a significant increase in peak intensity with a signal-
to-noise ratio >3. For the M1G DNA adduct, specificity could not
be thoroughly assessed by comparison of blank and fortified
samples, since the matrix DNA contained endogenous levels of
M1G. However, no other matrix substances significantly inter-
fered with the analysis of M1G (signal-to-noise ratio >3) and
spiking of three different levels of M1G (0.25, 0.50 and
0.75 ng mL1) to CT-DNA did significantly increase the M1G peak
area at the expected RT.
3.2.2. Selectivity
The methods' selectivity could be demonstrated by analyte
identification based on relative RT (ratio of analyte RT and corre-
sponding internal standard RT) and the accurate mass of their
positive ions ([MþH]þ). Only chromatographic peaks of interest
with signal-to-noise ratios that exceeded 3 were taken into account
and tolerance levels for relative RT and maximum mass deviation
were established at 2.5% and 5 ppm respectively.
3.2.3. Linearity
Linearity was assessed by deploying 2 separate calibration
curves in triplicate. A first calibration curvewas established in a low
range that would enable quantification of endogenous and exoge-
nous levels of DNA adducts [3,24], whereas the second calibration
curvewas used to enable the in vitro application of this method (see
“DNA adducts in CT-DNA treated with genotoxic compounds”). Forthe calibration curves, the matrix DNA was fortified with 0.025;
0.05; 0.075; 0.1; 0.125; 0.25; 0.50; 0.75; 1; 1.25; 2.5; 5; 7.5; 10 and
12.5 ng mL1 O6-CMG, O6-MeG, M1G and CroG. The obtained co-
efficients of determination (R2) proved to be over 0.99, suggesting a
good to excellent linearity, which could be confirmed bymeans of a
one-way ANOVA (F-test) linearity test (P > 0.05). The ANOVAmodel
was constructed with the detected area ratio of each component
(DNA adduct peak area/area of the internal standard) as the
dependent variable and the calibration curve concentration levels
as the independent variable (SPSS Statistics 21).3.2.4. Mean recovery
To assess mean recovery of the targeted compounds, 3 series of
six replicates of the earlier described CT-DNA samples fortifiedwith
three different spike levels were utilized. As M1G appeared to be
endogenously present in CT-DNA, total concentrations were
adjusted to the measured fortified concentrations prior to calcu-
lation of the corrected mean recovery. Mean recovery of M1G, CroG
and O6-MeGwerewithin the narrow range of 97 and 104% and thus
proved to be excellent. O6-CMG mean recoveries ranged between
89 and 108%, which is still well within the acceptable range of
80e120%.3.2.5. Precision
To evaluate precision, repeatability and intra-lab reproduc-
ibility were determined by calculation of the relative standard
deviations (RSD%). Three sets of six fortified samples (equals the
three fortification levels with six replicates each) were analyzed to
test repeatability. One additional set of six samples fortified,
Fig. 2. Mass spectrum of O6-MeG (a), d3-MeG (b), O6-CMG (c), M1G (d), 13C3-M1G (e), CroG (f) and 13C15N2-CroG (g) in CT-DNA with HRMS acquisition.
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enabled assessment of intra-lab reproducibility. As no detectable
O6-CMG, O6-MeG and CroG levels appeared to be present in the
matrix, and since endogenous levels in different tissues demon-
strate a certain variation, fortification levels for O6-CMG were
selected according to the estimated limit of detection and quan-
tification with the full HRMS method. To establish M1G levels, the
endogenous levels of M1G in the matrix DNA were taken into
account. For CroG and O6-MeG, spike levels were adjusted to those
of M1G and O6-CMG respectively, due to their analogue nature and
origin. Also, for M1G, the endogenously present M1G DNA adduct
levels in the CT-DNA were subtracted from the total measured
M1G concentrations in spiked CT-DNA prior to calculation of the
final/fortified concentration and RSD%. For M1G, CroG and O6-
MeG, repeatability appeared to be excellent since RSD% consis-
tently proved below 4% for each analyte and fortification level. In
comparison, repeatability for O6-CMG was less good, but still
below the acceptable RSD% limit of 15 with a RSD% of 9. Intra-lab
reproducibility for all targeted compounds is good as well, with all
RSD% below 9.3.2.6. Limits of detection and quantification
LOQs were determined at a minimal signal-to-noise ratio of 10,
whereas limits of detection (LODs) required a signal-to-noise ratio
of at least 3 (Table 2). LODs and LOQs with SIM-MS and SIM-MS/MS
clearly overthrew the full HRMS LODs and LOQs for O6-CMG and
O6-MeG. For CroG and M1G, differences in LODs and LOQs between
full HRMS, SIM-MS and SIM-MS/MS were less pronounced. Prac-
tical assessment of LOD and LOQs for M1G is limited by the pres-
ence of M1G levels inherent to the CT-DNA matrix. Therefore,
average LOD and LOQs levels for M1G were assessed based on
cochromatography of added M1G with endogenously present M1G
in the CT-DNA matrix.
For the combined detection and quantification of all 4 targeted
DNA adducts, SIM-MS/MSwould be preferred over SIM-MS and full
MS since it combines the lowest LOQs for all 4 targeted compounds.3.3. Development of a diet-related DNA adduct database to
facilitate interpretation of untargeted DNA adductomics studies
To construct an in-house database, literature was searched for
DNA adducts of which harmful exogenous levels may be linked to
the human diet. The main focus of the search were DNA adduct
types originating from DNA alkylation or oxidation since these re-
action types are of particular interest regarding the mechanisms
behind colon cancer initiation and promotion by red and processed
meat consumption [8,25]. The retrieved DNA adducts were
assembled in a database which currently contains 123 different
diet-related DNA adducts (Supporting information Table 1).
By means of ToxID™ software (Thermo Fisher Scientific, San
Jose, USA) and the self-constructed database, the full scan HRMS
spectra of different DNA samples could be screened for the pres-
ence of non-targeted diet-related DNA adducts in retrospect. The
considered inclusion criteria consisted of a minimal signal intensity
of 10,000, a maximum mass deviation of 10 ppm, recurrence and
stable RT of the DNA adduct of interest in replicate and repeat
samples and a C12/C13 ratio approaching the natural 99:1 ratio.
Detection of a certain diet-related DNA adduct with full MS and
Tox-ID™ profiling renders chromatograms and data on measured
peak area of the masses of interest and can thus suggest the pres-
ence of a putative DNA adduct in a sample. If believed relevant,
exact confirmation of DNA adduct identity can be made by use of
commercially available analyte standards.
In this study, normalization of the obtained untargeted DNA
adduct Tox-ID™ data was based on the measured signal intensity
(area) of the guanine nucleobase in each sample by expressing DNA
adduct area relative to guanine area. The identity of guanine was
confirmed with an analytical standard.
To demonstrate the possible merit and application of the
described approach, full HRMS spectra obtained from blank CT-
DNA, CT-DNA treated with KDA, MDA and CRO, and also tumor
biopsies were interpreted by means of ToxID™ profiling and the
self-constructed database. The results are discussed in the related
sections below and documented in Fig. 3.
Table 2





















O6-CMG 1.25 89.5 ± 9.0 8.4 ± 4.8 5.6 888 22.2 22.2
2.50 107.9 ± 4.4 7.0 ± 2.9 5.8
3.75 106.6 ± 3.1 7.1 ± 2.9 8.3
O6-MeG 1.25 103.8 ± 0.8 1.7 ± 0.2 3.6 28.1 28.1 2.82
2.50 100.2 ± 1.8 2.5 ± 0.4 1.8
3.75 101.6 ± 1.5 1.5 ± 0.6 2.1
M1G 0.125 103.3 ± 0.3 3.7 ± 1.5 4.4 2.48 2.48 4.96
0.250 97.3 ± 1.9 2.5 ± 0.5 6.9
0.375 100.2 ± 0.5 2.1 ± 0.7 3.8
CroG 0.125 97.4 ± 1.4 2.2 ± 0.8 5.8 0.52 1.05 4.20
0.250 97.0 ± 1.3 2.8 ± 0.9 3.9
0.375 98.0 ± 2.0 1.8 ± 1.0 3.6
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The commercially available CT-DNA contained endogenous
levels of M1G, whereas no detectable endogenous levels of O6-
MeG, O6-CMG and CroG could be detected.
Next to the targeted cyclic M1G DNA adduct, Tox-ID™ profiling
indicated the possible presence of 20 additional DNA adducts
(Fig. 3). This includes M1A (oxopropenylA), M1C (oxopropenylC),
1,N2-ethenoG, non-O6-carboxymethylG, two non-O6-methylGs,
carboxyethylG, FapyG (formamidopyrimidineG), FapyA (for-
mamidopyrimidineA), methylT, dimethylT or ethylT, carbox-
ymethylT, carboxyethylT, methoxymethylC, methoxymethylT,
butylG, hydroxyethylG, propylG, trimethylG and hydroxyG DNA
adducts (Fig. 3).
3.5. DNA adducts in CT-DNA treated with genotoxic compounds
Upon addition of different concentrations of KDA, MDA and CRO
to CT-DNA, O6-MeG, O6-CMG, M1G and CroG DNA adducts were
formed during overnight incubation. O6-CMG and O6-MeG were
formed upon addition of KDA, CroG was formed due to addition of
CRO and M1G was produced after the addition of MDA; a clearFig. 3. Heat map of DNA adduct profiling in CT-DNA and colon tumors: white to yellow an
guanine area ratio), respectively. Blank CT-DNA data are presented on the left (CT0) and K1
(potassium diazoacetate), MDA (malondialdehyde) and CRO (crotonaldehyde) on DNA add
interpretation of the references to colour in this figure legend, the reader is referred to thedoseeresponse effect was observed (Fig. 4). Based on the fact that
lipid peroxidation products are highly reactive chemicals, and also
based on practical assessment of the experimental setup, MDA and
CRO concentration levels were adjusted to avoid overload of the LC
and MS system. Therefore, the added MDA and CRO concentrations
are lower than the added KDA concentrations.
Addition of KDA to DNA also resulted in the formation of
untargeted DNA adducts (Fig. 3). A first observation was the
possible presence of 2 additional methylG compounds other than
O6-MeG at RTs of 1.7 and 2.3 min. Both additional MeG DNA ad-
ducts were more prevalent than O6-MeG. In addition to MeG, a
slight increase in butylG, methoxymethylC and a significant in-
crease in methylT and carboxymethylT could be noted after KDA
treatment.
During screening of CT-DNA treated with MDA by means of the
DNA adduct database, it could be observed that not only M1G, but
also M1A and M1C levels appeared to increase in a doseeresponse
manner when the MDA concentration was raised (Fig. 3). In addi-
tion, just like KDA, MDA conceivably promoted the formation of
methoxymethylC.
Untargeted analysis of CT-DNA samples that had been treated
with CRO revealed the probable presence of methoxymethylC,d red to black represent low to high DNA adduct signal intensity (DNA adduct area to
eK3, M1eM3 and C1eC3 show the effect of rising concentrations of respectively KDA
uct profile. Individual biopsy data are presented on the right (tumor (T) 1 to 10). (For
web version of this article.)
Fig. 4. Mean (±sd) O6-MeG, O6-CMG, CroG and M1G DNA adduct formation in CT-DNA
after exposure to genotoxic chemicals. Level 0 corresponds to the negative control
samples. Level 1 represents addition of 1 mM of KDA or 0.1 mM of CRO or MDA. Level 2
equals addition of 2.5 mM of KDA or 0.25 mM of CRO or MDA. Level 3 demonstrates
addition of 5 mM KDA or 0.5 mM of CRO or MDA.
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O6-CMG could be identified and quantified in 8 out of 10 tumor
samples. For quantification of O6-CMG in each sample, the DNA
adduct concentrations were adjusted according to the measured
DNA concentration in each sample. The mean amount of O6-CMG
equaled 815 adducts per 108 nucleotides, with a relatively high
interindividual variability (range from < LOD to 1630 adducts per
108 nucleotides). M1G, CroG and O6-MeG could not be detected.
Untargeted analysis of all tumor samples (T1-T10) was carried
out in parallel. The list of observed DNA adducts includes both
alkylation and oxidation DNA adducts, i.e. non-O6-CMG (samemass
as O6-CMG, but a different RT), butylG, hydroxyethylG, carbox-
yethylA, carboxymethylA, methylT, dimethylT or ethylT, carboxyT,
FapyG, FapyA, Tglycol, hydroxyT, 1,N2-ethenoG, N2,3-ethenoG, 1,N6-
ethenoA, M3C and methoxymethylG (Fig. 3).4. Discussion
A new UHPLC-HRMS/MS method was developed to enable tar-
geted and untargeted detection of both known and unknown DNA
adducts. A first focus was the separation and targeted detection of
O6-CMG, O6-MeG, M1G and CroG. These DNA adducts are of
particular interest because DNA-damaging NOCs and lipid peroxi-
dation products appear to be the two main culprits in the complex
underlying mechanism that links red and processed meat con-
sumption to an elevated colon cancer risk [8,25]. The combined
targeted detection of O6-CMG, O6-MeG, M1G and CroG is unique as
it permits simultaneous investigation of 2 important but very
different pathways. Furthermore, at the time, this is the only
described MS-based method to combine the detection of O6-CMG,
O6-MeG, M1G and CroG.
DNA adductomics is an up-and-coming approach to investigate
DNA adduct formation and its possible link to chronic disease. To
elucidate supplementary meat or colon cancer related DNA adduct
types and pathways, the use of this UHPLC-HRMS method was
investigated in vitro and in vivo ensuring valid future clinical
application in DNA adductomic studies. To the best of our knowl-
edge, this paper describes 1 of only 3 high resolution MS-based
DNA adductome mapping methods, whereas it is the first toexplore and illustrate the use of Quadrupole-Orbitrap technology
for DNA adduct profiling purposes.
Supplementary, an in-house database that lists known DNA
adducts, was constructed and implemented to facilitate the com-
plex process of omics data interpretation.
4.1. DNA adduct analysis with UHPLC-HRMS/MS
All relevant performance characteristics of the MS method were
in accordance with internationally accepted analytical criteria.
However, because of the method's intended use in a clinical setting,
most attention was paid to the achievable LODs and LOQs for the 4
targeted DNA adducts prior to in vitro and/or in vivo SIM-HRMS/MS
method application.
The in vivo relevance of the detection of O6-CMG has been
demonstrated by its qualitative detection in several biological
samples like blood, colon biopsies and exfoliated colonocytes
[26e28]. To the best of our knowledge, average endogenous levels
of O6-CMG in human tissue have not yet been reported. Therefore,
at present, a scientifically based statement on the applicability of
this method for the quantification of possibly low endogenous O6-
CMG DNA adduct levels is not possible. Cupid et al. described the
measurement of 35e80 O6-CMG DNA adducts per 108 nucleotides
in blood of volunteers consuming a high meat diet [28]. These DNA
adducts levels were detected by means of Immunoslot Blot with an
LOD of 15 adducts per 108 nucleotides, which confirms the
competitiveness of our targeted SIM-HRMS/MS method.
A correct quantification of endogenous levels of the O6-MeG
DNA adduct with an LOQ of 2.82 adducts per 108 nucleotides with
MS/MS acquisition will depend on tissue or cell type. For example,
Kang et al. reported the detection of less than one O6-MeG DNA
adduct in 108 nucleotides in leucocyte DNA, whereas more than
two O6-MeG adducts per 108 nucleotides appeared to be present in
hepatic DNA [3,29]. This suggests that our current method allows
detection and quantification of O6-MeG in a clinically relevant
range. If required, the current LOQ and LOD could be improved by
tweaking the MS and HESI settings. However, at the time, all set-
tings were optimized for the simultaneous detection of all 4 tar-
geted DNA adducts and for O6-CMG, demonstrating the highest
LOQ and LOD, in particular.
The retrieved LOQs for M1G and CroG (<5 adducts per 108 nu-
cleotides) appeared to be more than sufficient. Indeed, according to
previously reported endogenous levels of M1G and CroG in several
tissue types, all reported DNA adduct levels exceeded 6 adducts per
108 nucleotides [3], which implies that our LOQs are below
endogenously present M1G and CroG DNA adduct levels.
4.2. In vitro application
The presence of both targeted and untargeted DNA adducts
were investigated in blank CT-DNA or CT-DNA treated with geno-
toxic chemicals to demonstrate the in vitro application of the
described method and the in-house constructed database.
In blank CT-DNA samples, different DNA adducts could be
retrieved. M1G appeared to be the sole detected targeted DNA
adduct endogenously present in CT-DNA and similar amounts of
M1G in CT-DNA have been reported before [30]. Using the untar-
geted HRMS approach, the accurate masses of 20 additional com-
pounds (Fig. 3) could be linked to DNA adducts included in the self-
constructed diet-related DNA adduct database (see Supporting
information Table 1), resulting in a putative identification. The
endogenous or exogenous occurrence of several of these DNA ad-
ducts in DNA and their link to for example oxidative stress [31,32],
exposure to environmental carcinogens [33,34] and carcinogenesis
[32,35], have been reported previously, acknowledging their
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Treatment of CT-DNA with KDA, MDA and CRO resulted in the
formation and detection of the 4 targeted DNA adducts. The
demonstrated dose response effect was to be expected for KDA, a
well-known NOC, and both O6-MeG and O6-CMG, since the
methylation and carboxymethylation of deoxyguanosine at the O6
position by nitrosated glycine derivatives have been documented in
the past [19,36]. The demonstrated formation of M1G in CT-DNA by
attack of the G base by the highly reactive lipid peroxidation
product MDA has also been reported extensively in literature, with
M1G being the predominantly formed DNA adduct [37]. The same
applies for CRO and CroG formation [9]. The more ‘efficient’ and
pronounced interaction of MDA and CRO with DNA to form M1G
and CroG, compared to the interaction of KDAwith DNA to form O6-
CMG and O6-MeG (lower added MDA and CRO concentrations
(compared to KDA) yield similar DNA adduct concentrations; Fig. 4)
can be explained by the highly reactive nature of lipid peroxidation
products [31].
Next to the detection of targeted DNA adducts, application of the
HRMS method also enabled the detection of untargeted DNA ad-
ducts. Rapid putative identification of these compounds in retro-
spect was empowered by the use of the self-constructed database.
In total, 25 untargeted DNA adducts were detected in blank CT-DNA
and/or upon treatmentwith KDA,MDA and/or CRO. Several of these
putatively identified DNA adducts have been detected previously
and described in literature (Supporting information Table 1),
acknowledging their relevance. Retrieval of these DNA adducts
clearly emphasizes the potential of the HRMS method for DNA
adductome mapping and the ease of putative DNA adduct identi-
fication by means of our DNA adduct database.
Some of the untargeted DNA adducts reported above have not
been investigated extensively. However, considering the possible
detection of all these compounds after incubation of DNAwith KDA,
MDA or CRO, further investigation is warranted. After all, extensive
research on the possible link between toxic endo- and exogenous
NOCs, lipid peroxidation products and disease has been conducted
in the past and has revealed a connection to an increased cancer
risk [38,39].
4.3. In vivo application
The described DNA adductomics method has been constructed
for future use in clinical studies. Therefore, preliminary tests for
in vivo application were conducted on 10 colon tumor tissue sam-
ples. This resulted in the detection of the O6-CMG DNA adduct in a
vast majority of colon tumor biopsies. The other 3 targeted com-
pounds could not be retrieved in any of the biopsy samples,
although they have been detected in different human tissue types
before [3], thus suggesting that M1G, CroG and O6-MeGwere either
absent or no longer present above the LOD in the analyzed biopsies.
ToxID™ screening revealed the likely presence of 17 untargeted
DNA adducts of which some could be retrieved in all 10 biopsies,
whilst others could only be detected in some or just one sample(s).
Current knowledge on the stability of different DNA adducts is
still limited. In consequence, future DNA adduct profiling should be
carried out as soon as possible following tissue sampling to avoid
DNA adduct instability issues. As these possible stability issues
were not sufficiently taken into account during colon biopsy sam-
ple handling and storage, any conclusions obtained from the earlier
reported results on the possible connection between observed DNA
adduct levels and diet or disease status would be too precarious at
the time being. A more extensive discussion on DNA adduct
profiling and its link to diet and disease status will therefore be
conducted during extensive follow-up studies. Nonetheless, the
described DNA adductomics method already proved its usefulnessas both targeted and putative untargeted diet-related DNA adducts
were detected easily in vivo. Moreover, this is the first paper to
report DNA adductome mapping of (tumoral) colonic tissue.
To provide an overview, the envisioned workflow for DNA
adduct profiling in future DNA adductomic studies by means of the
reported UHPLC-HRMS(/MS) method is documented in the
graphical abstract.
4.4. The merit of a DNA adduct database
The human diet is quite complex and person-dependent, which
implies that the impact of the individual human diet is very hard to
pin to down. As diet and lifestyle significantly contribute to colon
cancer risk, further investigation is warranted to link dietary
toxicity to chronic disease through DNA adduct formation. Different
diet-related DNA adduct types can be formed by alkylation and
oxidation or mycotoxin, heterocyclic amine (HCA), PAH, acrylamide
exposure, etc. In this context, a total of 123 different DNA adducts
have currently been listed in an in-house (diet-related) DNA adduct
database. Most of the listed DNA adducts have already been
investigated in vitro or in vivo in relation to one or multiple ‘sus-
picious’ foodstuffs (see Supporting information Table 1 for detailed
references). As the currently available information concerning the
genotoxic effects of different food constituents is quite elaborate,
yet still inconclusive, and since the use of DNA adductomics is still
under development, it may be stated that although our DNA adduct
list (Supporting information Table 1) is already quite extensive, it is
not definite. Nevertheless, due to the complex nature of the human
diet and the long list of related research questions, the database can
definitely help expose relevant DNA adduct types that require a
more extensive investigation.
As different heterocyclic amine, polycyclic aromatic hydrocar-
bon, mycotoxin and acrylamide generated DNA adducts were also
included in the database, the untargeted UHPLC-HRMS approach
and database can also be put to use in related research that focuses
on other diet-related chronic diseases. Furthermore, the self-
constructed database includes a multitude of DNA adducts gener-
ated by unspecific alkylation and oxidation reactions which could
be caused by several types of genotoxic, mutagenic and carcino-
genic chemicals.
5. Conclusion
Hybrid HRMS systems yield highly specific information on
compound mass, elemental composition and identity, whilst also
enabling study of fragmentation patterns offering several advan-
tages regarding structural elucidation. In consequence, such MS
systems are particularly well suited for DNA adductomics [12,40].
As it is our goal to implement the described method in the search
for DNA adduct formation through dietary exposure to genotoxic
chemicals in the meatecancer relationship, the newly developed
and successfully validated UHPLC-HRMS(/MS) method currently
combines the simultaneous detection of 4 structurally and chemi-
cally different DNA adducts. The obtained LODs and LOQs for the
targeted detection of O6-CMG, O6-MeG, M1G and CroG with SIM-
MS/MS allow in vitro and in vivo application. The state-of-the-art
hybrid MS method also showed great promise for untargeted
DNA adduct detection in future DNA adductomic studies as the
Orbitrap revealed the presence of several putatively identified DNA
adducts in different DNA samples. This confirms the applicability of
the untargeted full scan HRMS approach and its envisioned use for
DNA adductome mapping. The use of the in-house DNA-adduct
database in research focusing on diet and lifestyle related chronic
diseases could expedite exposure of relevant biomarkers and pro-
vide new insights in disease etiology and prevention. The described
L.Y. Hemeryck et al. / Analytica Chimica Acta 892 (2015) 123e131 131adductomics methodology and database will thus serve as a basis
for the analysis of both endogenous and exogenous DNA adducts in
DNA from several tissue types and for a wide variety of research
topics.
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